TY - JOUR
T1 - Impaired Vascular Endothelial Growth Factor A and Inflammation in Patients with Peripheral Artery Disease
AU - Gardner, Andrew W.
AU - Parker, Donald E.
AU - Montgomery, Polly S.
AU - Sosnowska, Danuta
AU - Casanegra, Ana I.
AU - Esponda, Omar L.
AU - Ungvari, Zoltan
AU - Csiszar, Anna
AU - Sonntag, William E.
PY - 2014/9
Y1 - 2014/9
N2 - We compared apoptosis, cellular oxidative stress, and inflammation of cultured endothelial cells treated with sera from 130 patients with peripheral artery disease (PAD) and a control group of 36 patients with high burden of comorbid conditions and cardiovascular risk factors. Second, we compared circulating inflammatory, antioxidant capacity, and vascular biomarkers between the groups. The groups were not significantly different (P >.05) on apoptosis, hydrogen peroxide, hydroxyl radical antioxidant capacity, and nuclear factor κ-light-chain enhancer of activated B cells. Circulating tumor necrosis factor α (TNF-α; P =.016) and interleukin 8 (IL-8; P =.006) were higher in the PAD group, whereas vascular endothelial growth factor A (VEGF-A; P =.023) was lower. The PAD does not impair the endothelium beyond that which already occurs from comorbid conditions and cardiovascular risk factors in patients with claudication. However, patients with PAD have lower circulating VEGF-A than the control group and higher circulating inflammatory parameters of TNF-α and IL-8.
AB - We compared apoptosis, cellular oxidative stress, and inflammation of cultured endothelial cells treated with sera from 130 patients with peripheral artery disease (PAD) and a control group of 36 patients with high burden of comorbid conditions and cardiovascular risk factors. Second, we compared circulating inflammatory, antioxidant capacity, and vascular biomarkers between the groups. The groups were not significantly different (P >.05) on apoptosis, hydrogen peroxide, hydroxyl radical antioxidant capacity, and nuclear factor κ-light-chain enhancer of activated B cells. Circulating tumor necrosis factor α (TNF-α; P =.016) and interleukin 8 (IL-8; P =.006) were higher in the PAD group, whereas vascular endothelial growth factor A (VEGF-A; P =.023) was lower. The PAD does not impair the endothelium beyond that which already occurs from comorbid conditions and cardiovascular risk factors in patients with claudication. However, patients with PAD have lower circulating VEGF-A than the control group and higher circulating inflammatory parameters of TNF-α and IL-8.
UR - http://www.scopus.com/inward/record.url?scp=84905911046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905911046&partnerID=8YFLogxK
U2 - 10.1177/0003319713501376
DO - 10.1177/0003319713501376
M3 - Article
C2 - 24006146
AN - SCOPUS:84905911046
SN - 0003-3197
VL - 65
SP - 683
EP - 690
JO - Angiology
JF - Angiology
IS - 8
ER -